Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04840264 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2026 to Dec 31, 2027
    • Study completion date: Jun 30, 2027 to Jun 30, 2028
    • Study site revised
    • Collaborators expanded, about 4 words
    v7
  2. Primary completion date: Feb 28, 2024 to Dec 31, 2026
    • Study completion date: Jan 1, 2025 to Jun 30, 2027
    v6
  3. Primary endpoint revisedv5 Show 6 more changesShow less
    • Enrollment target: 89 to 79
    • Interventions: 5Fluorouracil (Drug), Docetaxel (Drug), Oxaliplatin (Drug) to Docetaxel (Drug), Fluorouracil (Drug), Oxaliplatin (Drug)
    • Eligibility criteria shortened, about 113 words
    • Secondary endpoints revised (6)
    • Study description expanded, about 3 words
    • Study title shortened, about 3 words
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruitingv3 Show 9 more changesShow less
    • Primary completion date: Jan 1, 2023 to Feb 28, 2024
    • Start date changed from estimate of Jul 1, 2021 to Jan 7, 2022
    • Enrollment target: 108 to 89
    • Study completion date: Jan 1, 2024 to Jan 1, 2025
    • Eligibility criteria expanded, about 195 words
    • Secondary endpoints: 4 to 6
    • Site details revised
    • Study description expanded, about 1 word
    • Study title expanded, about 2 words
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.
Trial Details
NCT Number NCT04840264
Lead Sponsor Sixth Affiliated Hospital, Sun Yat-sen University
Collaborators: Guangdong Provincial People's Hospital
Conditions
(from sponsor)		 Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Related terms Peritoneal Neoplasms
Enrollment 79 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov